西罗莫司片在中国上市了吗？

Is (sirolimus) available in China? It's on the market. In September 1999, the US FDA approved its use to prevent organ transplant rejection. In 2003, sirolimus tablets (sirolimus) were launched in China and used to treat kidney transplant patients with remarkable results.

Although sirolimus tablets (sirolimus) are structurally homologous to TRL (Tacmlimus, FK506) and bind to the same immune-binding protein, their mechanisms of action are different. SRL inhibits the activity and proliferation of T cells and also inhibits the production of antibodies. In cells, SRL combines with the immunosuppressive protein FKBP 12 to produce an immunosuppressive complex.

Current research shows that sirolimus suppresses the body's immune function by affecting unique cell signaling pathways. Sirolimus and FK506 share the same receptor in the body, namely FK506 immunobinding protein (FKBP). After sirolimus binds to FKBP, on the one hand, it inhibits the activation of 70-KSU6 kinase (p7), preventing the ribosome 40S subunit S6 protein from phosphorylating g7, affecting protein synthesis; on the other hand, it inhibits Cyclin D2, D3 The expression of cell cycle-dependent kinases, namely cdk4 and cdk6, and the activation of Cyclin E-cdk2 complex make cells stagnant in the middle and late stages of GI and unable to continue to proliferate. Its direct target may be a protein mammalian'rOR (mTOR) that has a homologous sequence to phospholipid phthaloinositide kinase. That is, the combination product of the sirolimus and FKBP complex with mTOR can block the immune response triggered by the activation of mTOR by the H, -2, U, -15 or CD28/B7 costimulatory pathways, thereby exerting a powerful immunosuppressive effect.

The above is the launch time of sirolimus tablets (sirolimus) in China and its effects provided by our medical companion travel. From this point of view, the effect of sirolimus (sirolimus) in treating kidney transplantation is relatively ideal, and patients can use it with confidence.

Recommended related hot articles: /newsDetail/76929.html